Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Same Day Discharge in NSTE-ACS: Is It Possible?

At present, percutaneous coronary intervention (PCI) is the most common coronary revascularization strategy. One of its benefits is that patients can be safely discharged when procedures are programed, which helps decompress hospital capacity. 

¿Es posible el alta en el mismo día en los síndromes coronarios agudos sin elevación del segmento ST?

However, this strategy has not been validated for acute coronary syndromes; the evidence gathered for non-ST elevation ACS is far from robust, and therefore is not recommended by guidelines. 

It might be validated for low risk NSTE-ACS.

1385 NSTE-ACS cases treated with non-elective PCI were analyzed. 300 of these cases (19.6%) were discharged on the same day (SDD) and 1085 the following day (NDD).

Primary end point was readmission for any cause at 30 days. 

SDD patients were evaluated within 4-6 hours after procedure. If there were no complications, they were considered for discharge. 

Mean age was 62, there were no differences in hypertension, diabetes, COPD, dialysis, peripheral vascular disease or CABG. TIMI and GRACE scores were similar. 11% received IIb IIIa inhibitors.  

Read also: Thromboendarterectomy vs. Endovascular Therapy in Common Femoropopliteal Territory. Is Surgery Still the Gold Standard?

The SDD group showed lower increase of biomarkers and anemia. The use of the transradial approach was more frequent and anatomy was less complex in this group. 

The presence of unstable angina was higher in patients receiving SDD and NSTE-ACS in those receiving NDD.

There was no difference in stent use, treated artery, number of treated vessels or the use of IVUS.

In the SDD group discharge was seen more often during the morning (vs. the other cohort, more often discharged during the afternoon). 

Read also: High Risk of Bleeding after PCI: More Evidence for Short DAPT.

Hospital stay was 8 hours in the SDD cohort and 26 in the NDD group. 

Primary end point was more frequent in the NDD group (OR = 1.6 [1.01-2.57]; P < 0.01)

There were no differences in mortality and bleeding at 30 days and one year. 

Factors associated with SDD were: male sex, transradial approach, negative biomarkers and time of procedure. 

After propensity score matching, there were no differences in readmissions and mortality at 30 days. 

Conclusion

SDD after non-elective PCI for NSTE-ACS might be a valid alternative to NDD in selected low risk patients, seeing as it was comparable in mortality, bleeding and readmission rate. 

Original Title: Same day discharge following non-elective PCI for non-ST elevation acute coronary syndromes.

Reference: Essa Hariri, et al. Am Heart J 2022;246:125–135.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...